Abstract
A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.
| Language | English (US) |
|---|---|
| Pages | 1180-1184 |
| Number of pages | 5 |
| Journal | Pancreas |
| Volume | 47 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 1 2018 |
Fingerprint
Keywords
- clinic trial
- drug development
- pancreatitis
- patient-reported outcomes
- study design
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology
Cite this
Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities : Overview summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop. / Uc, Aliye; Andersen, Dana; Borowitz, Drucy; Glesby, Marshall J.; Mayerle, Julia; Sutton, Robert; Pandol, Stephen J.
In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1180-1184.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities
T2 - Pancreas
AU - Uc, Aliye
AU - Andersen, Dana
AU - Borowitz, Drucy
AU - Glesby, Marshall J.
AU - Mayerle, Julia
AU - Sutton, Robert
AU - Pandol, Stephen J.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.
AB - A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.
KW - clinic trial
KW - drug development
KW - pancreatitis
KW - patient-reported outcomes
KW - study design
UR - http://www.scopus.com/inward/record.url?scp=85055076854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055076854&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001176
DO - 10.1097/MPA.0000000000001176
M3 - Article
VL - 47
SP - 1180
EP - 1184
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 10
ER -